肿瘤细胞治疗研究
英文原题：Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023.
本综述讨论了过去5年CAR-T细胞疗法在治疗非肿瘤疾病方面的进展和演变。
近年来，CAR-T 细胞疗法在治疗某些肿瘤方面取得的显著成功，促使大量研究探索其治疗非肿瘤疾病的潜在应用。本综述讨论了过去5年CAR-T细胞疗法在治疗非肿瘤疾病方面的进展与演变。此外，我们总结了CAR-T细胞疗法在治疗非肿瘤疾病中的优势与不足，并指出了应克服的困难。在对CAR-T技术的最新研究进行深入分析后，我们讨论了CAR-T疗法的关键要素，例如为非肿瘤疾病开发有效的CAR设计、控制应答速率和持续时间，以及实施降低毒性的安全措施。这些研究为不同的递送策略、新靶标分子的发现以及提高CAR-T疗法治疗非肿瘤疾病的安全性提供了新的见解。
Recently, the remarkable success of chimeric antigen receptor T cell (CAR-T) therapy in treating certain tumors has led to numerous studies exploring its potential application to treat non-oncology diseases. This review discusses the progress and evolution of CAR-T cell therapies for treating non-oncology diseases over the past 5 years. Additionally, we summarize the advantages and disadvantages of CAR-T cell therapy in treating non-oncological diseases and identify any difficulties that should be overcome. After conducting an in-depth analysis of the most recent studies on CAR-T technology, we discuss the key elements of CAR-T therapy, such as developing an effective CAR design for non-oncological diseases, controlling the rate and duration of response, and implementing safety measures to reduce toxicity. These studies provide new insights into different delivery strategies, the discovery of new target molecules, and improvements in the safety of CAR-T therapy for non-oncological diseases.
MEMBER ACCOUNT
登录成功会直接打开下一页。
